Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tiziana Life Sciences Ltd (NQ: TLSA ) 0.9100 +0.0100 (+1.11%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tiziana Life Sciences Ltd < Previous 1 2 3 4 Next > Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data November 01, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million October 30, 2024 Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study October 30, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease September 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Appoints New Chief Executive Officer August 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule August 14, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Granted FDA Fast Track Designation July 24, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Receives $3.4 Million in Non-Dilutive Funding June 28, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab June 26, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis June 11, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 From FN Media Group LLC Via GlobeNewswire Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab June 06, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab June 04, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research May 30, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab May 13, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab April 25, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program April 23, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program April 22, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® April 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology April 18, 2024 Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology April 11, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease March 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients January 08, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 January 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation January 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis December 19, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar December 04, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis November 30, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 November 01, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
